Inline Raman Spectroscopy as a Process Analytical Technology Tool for Real-Time Concentration Monitoring and Mixing Endpoint Determination of an Oligonucleotide Drug Product
Pharmaceutical Research · 12.11.2026
DOI: 10.1007/s11095-026-04232-y ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceutical Research, online erschienen am 12.11.2026. Verfasst von Francis Kwofie und 3 weiteren Autor:innen. Beteiligte Einrichtung: Drug Product Development, Drug Development and Supply, GSK R&D, 1250 S. Collegeville Road, Collegeville, PA, 19426, USA. francis.x.kwofie@gsk.com. Die Arbeit nennt 73 Literaturangaben. Gefördert von: GlaxoSmithKline.
Abstract (Originalsprache)
BACKGROUND: Oligonucleotide drug product manufacturing commonly relies on time-consuming offline ultraviolet-visible (UV-Vis) spectroscopy and high-performance liquid chromatography (HPLC) analyses to confirm active pharmaceutical ingredient (API) concentration during mixing, providing limited process visibility. This study evaluated inline Raman spectroscopy as a process analytical technology (PAT) tool for real-time API concentration monitoring and mixing endpoint determination during manufacture of a model antisense oligonucleotide (ASO) drug product. METHODS: A partial least squares regression (PLSR) model was developed from inline Raman spectra using offline UV-Vis reference concentrations. Accuracy, linearity, range, precision, specificity, and robustness were evaluated, including effects of stirring speed, probe depth, and reusable versus single-use Raman optics. The validated model was applied to four ASO drug product batches manufactured in a 50-L single-use mixer. RESULTS: The PLSR model demonstrated good accuracy (RMSEP = 3.47 mg/mL), good linearity (R2 = 0.994 and 0.996 for calibration and independent prediction set, respectively), and precision (maximum %RSD = 1.12%). Minimal water interference supported specificity, and consistent performance across stirring speeds, probe depths, and Raman optic configurations demonstrated robustness. The procedure generated real-time ASO API concentration profiles and successfully determined the mixing endpoint for all four batches. CONCLUSIONS: Inline Raman spectroscopy coupled with PLSR provided accurate, specific, and robust real-time API concentration monitoring during oligonucleotide drug product manufacturing. The approach enabled real-time monitoring and objective mixing endpoint determination and may reduce reliance on offline measurements while improving process visibility and supporting more timely progression of manufacturing operations.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Drug Product Development, Drug Development and Supply, GSK R&D, 1250 S. Collegeville Road, Collegeville, PA, 19426, USA. francis.x.kwofie@gsk.com.
- Drug Product Development, Drug Development and Supply, GSK R&D, 1250 S. Collegeville Road, Collegeville, PA, 19426, USA.
Förderung
- GlaxoSmithKline
Zitieren
APA
Kwofie, F., Desai, P. M., Williams, S., & McLeod, A. (2026). Inline Raman Spectroscopy as a Process Analytical Technology Tool for Real-Time Concentration Monitoring and Mixing Endpoint Determination of an Oligonucleotide Drug Product. Pharmaceutical Research. https://doi.org/10.1007/s11095-026-04232-y
Vancouver
Kwofie F, Desai PM, Williams S, McLeod A. Inline Raman Spectroscopy as a Process Analytical Technology Tool for Real-Time Concentration Monitoring and Mixing Endpoint Determination of an Oligonucleotide Drug Product. Pharmaceutical Research. 2026. doi:10.1007/s11095-026-04232-y
BibTeX
@article{Kwofie2026,
author = {Kwofie, Francis and Desai, Parind M and Williams, Stephanie and McLeod, Anderson},
title = {Inline Raman Spectroscopy as a Process Analytical Technology Tool for Real-Time Concentration Monitoring and Mixing Endpoint Determination of an Oligonucleotide Drug Product},
journal = {Pharmaceutical Research},
year = {2026},
doi = {10.1007/s11095-026-04232-y}
}
EUVIMED